Capmatinib Hydrochloride

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricing Additional Novartis medicines will be made available through direct-to-patient platforms in 2026 Company remains committed to investing in markets that value innovation and implement policies that support broad and fast access to medicines Basel, December 19, 2025 – Novartis, a leading global innovative medicines company, today announced it has reached an agreement with the US government that aims to lower the price of innovative medicines in the US and support continued US investment in manufacturing, and research and development. Novartis has voluntarily agreed to take actions aimed at meeting the US Administration’s drug pricing priorities, including: Launching future medicines with comparable prices across high-income countries Building direct-to-patient platforms for Mayzent ® (siponimod), Rydapt ® (midostaurin) and Tabrecta ® (capmatinib). These new platforms will be accessible through TrumpRx Applying to participate in the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model aimed at further improving access to medicines in the US Medicaid program Supporting efforts to address the global imbalance in investment in pharmaceutical innovation “This agreement continues our long-term partnership with the US government to advance the development and manufacturing of breakthrough treatments for patients in the United States,” said Vas Narasimhan, CEO of Novartis. “We are committed to working with governments worldwide to ensure innovation is appropriately valued and that our medicines reach the patients who need them most.” Earlier this year, Novartis committed to investing $23 billion in expanding its US R&D and manufacturing infrastructure over 5 years. Since announcing this investment in April, the company: Announced a new $1.1 billion biomedical research hub in San Diego, CA Broke ground on a new flagship manufacturing hub in North Carolina, including three new facilities, in the Raleigh/Durham area. The hub will enable end-to-end manufacturing capabilities to produce medicines across the company’s technology platforms Opened a new radioligand therapy (RLT) manufacturing facility in Carlsbad, CA, enabling coast-to-coast manufacturing of RLTs Advanced plans to build new RLT manufacturing facilities in Florida and Texas In recognition of this investment, Novartis expects to receive three years of tariff relief. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release; or regarding potential future revenues from such products; or regarding our agreement with the US government aiming to lower the price of innovative medicines in the US; or regarding discussions of strategy, plans, expectations or intentions, including discussions regarding our continued investment into new US R&D capabilities and manufacturing. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. Neither can there be any guarantee that the expected benefits from the agreements and investments described in this press release will be achieved in the expected timeframe, or at all. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . # # # Novartis Media Relations E-mail: media.relations@novartis.com Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

The latest batch of accords brings the total number of most-favored-nation deals that the Trump administration has signed with major pharma companies to 14. Nine large pharma companies have reached agreements with the Trump administration to lower certain drug prices in the U.S.Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences, GSK, Merck & Co., Novartis, Roche’s Genentech and Sanofi have agreed with the White House to reduce the prices of certain prescription medicines in exchange for pharmaceutical tariff relief, President Donald Trump announced at an event Friday together with top U.S. health officials and senior executives from the companies.The latest batch of accords follows other similar “most favored nation” deals struck by Pfizer, AstraZeneca, Merck KGaA’s EMD Serono, Eli Lilly and Novo Nordisk in recent months.Trump sent letters to the leaders of 17 large pharma companies back in July demanding them to match U.S. prices of their new drugs with the lowest prices offered in other developed nations, which underscores the concept of the most-favored-nation (MFN) pricing.AbbVie, Johnson & Johnson and Regeneron are the remaining drugmakers on Trump’s list. Deals with those companies may not be too far away; Trump said these three firms, specifically highlighting J&J, will come to the White House next week, but he was then reminded it will happen after the holiday. J&J has been talking with the Trump administration “since day 1, even before day 1,” J&J CEO Joaquin Duato said on the company’s third-quarter earnings call in October. The company is looking to find “common ground” with the administration on shared priorities, the CEO added. The exact terms of the deals so far have mostly remained confidential. According to Trump, the companies will offer some of their medicines in the U.S. at the lowest prices in the developed world.For Amgen, the California company said it will expand its direct-to-patient program, AmgenNow, to include migraine prevention drug Aimovig and Humira biosimilar Amjevita at 60% and 80% discounts from their current U.S.list prices, respectively.BMS said it will soon provide its Pfizer-partnered anticoagulant Eliquis for free to Medicaid and that it will “donate more than seven tons of Eliquis active pharmaceutical ingredient (API) to ensure American supply chain resilience.” As an old drug, Eliquis is slated to face a major Medicare price reduction as part of the Inflation Reduction Act. Gilead is offering discounts on certain existing medicines for HIV, hepatitis and COVID-19 through Medicaid to bring them on par with other developed countries, the company said. The firm will offer its hepatitis C drug Epclusa at a 90% discount through TrumpRx.gov, a new direct-to-consumer drug purchasing platform operated by the federal government, according to a White House fact sheet. Merck plans to provide three of its diabetes products—Januvia, Janumet and Janumet XR—through a direct-to-patient program “at affordable prices,” according to the company's press release. The New Jersey pharma said it plans to include its experimental oral PCSK9 drug enlicitide in the future following a potential FDA approval. In what appears to be part of the MFN deal, the FDA has granted Merck a Commissioner’s National Priority Voucher (CNPV) for enlicitide for lowering LDL cholesterol. Another Merck candidate, TROP2-directed antibody-drug candidate sacituzumab tirumotecan (sac-TMT), also received a CNPV that will significantly reduce the FDA’s review time of the cancer treatment in the future.Sanofi said it will offer some of its medicines “at the same prices available to other high-income nations.” The move will reduce prices by an average of 61% for certain medicines for diabetes, cardiovascular and neurological conditions and cancer, the company said. Some of the French pharma's offerings will also be available through TrumpRx.gov.GSK said it will make most of its inhaled respiratory disease therapies and other products available to patients on a direct purchasing platform, with savings of up to 66%.Novartis will also offer its multiple sclerosis drug Mayzent and cancer drugs Rydapt and Tabrecta through TrumpRx. Among them, Mayzent will come at a 89% discount from its list price, according to the White House fact sheet.Meanwhile, Genentech’s flu drug Xofluza and Boehringer’s diabetes med Jentadeuto will be accessible on TrumpRx at $50 and $55, respectively, representing discounts of 70% and 90%, respectively. Previously, for Lilly and Novo, MFN deals involved their popular diabetes and obesity drugs offered through DTC channels or through Medicaid and Medicare.For Pfizer, which was the first Big Pharma to reach a deal with the administration, the New York pharma is offering discounts for some of its drugs through TrumpRx.gov. Pfizer also agreed to offer certain drugs at MFN prices to Medicaid. While Trump in his letters to the 17 companies demanded the lowest available prices in the U.S., the actual determination of MFN benchmarks might not be as harsh as some may have feared.In November, the Centers for Medicare & Medicaid Services (CMS) unveiled a voluntary initiative called the GENEROUS model, which is designed to implement MFN pricing in participating state Medicaid programs for outpatient drugs. Under that model, the benchmark used to calculate the MFN prices is actually the “second lowest country-specific manufacturer-reported net price, adjusted by gross domestic product per capita using a purchasing power parity method,” according to the CMS.The country basket for price comparisons includes the U.K., France, Germany, Italy, Canada, Japan, Denmark and Switzerland, according to the agency.This model is scheduled to begin in January 2026 and will run for five years until the end of 2030.In its Dec. 19 release, Novartis said it will apply to participate in the GENEROUS model and will launch future medicines at prices comparable to those from other high-income countries. Besides the drug pricing components of the deals, drugmakers have also committed to increasing their investments in the U.S. to win over the White House. These investments are typically a combination of manufacturing expansions, R&D expenditures and business development activities. These funding pledges were made before MFN deals in response to Trump’s threat of tariffs on pharmaceuticals.